Psychopharmacologic Drugs : Antipsychotics
IINVE1 “Invega Sustenna ER injectable suspension” 100 mg (paliperidone palmitate 156mg) /ml, 1.5 ml/cartridge
IINVE2 “Invega Sustenna ER injectable suspension 100 mg (paliperidone palmitate 156mg) /ml, 1 ml/cartridge
適應症：精神分裂症。
Usual dose:
IM, with a dose of 234 mg on treatment day 1 and 156 mg one week later, both administered in the deltoid muscle. The recommended monthly maintenance dose is 117 mg; some patients may benefit from lower or higher maintenance doses within the recommended range of 39 mg to 234 mg based on individual patient tolerability and/or efficacy. Following the second dose, monthly maintenance doses can be administered in either the deltoid or gluteal muscle.
Dose adjustment:
Renal impairment, mild (CrCl 50 mL/min to less than 80 mL/min): initiate with 156 mg IM on day 1 and 117 mg IM 1 week later; maintenance, 78 mg IM monthly
Renal impairment, moderate to severe (CrCl less than 50 mL/min): use not recommended.
Adverse effect:
Common: tachycardia, increased prolactin level, weight gain, dystonia, extrapyramidal disease, headache, somnolence.
Serious: agranulocytosis, seizure, tardive dyskinesia, neuroleptic malignant syndrome.
健保使用規範：
1.需合乎衛生主管機關許可之適應症範圍，並需符合下列條件(1)開始使用「第二代抗精神病藥品」時需於病歷記載：醫療理由或診斷，以及臨床整體評估表(CGI)之分數；(2)經規則使用六至八週後，需整體評估其療效，並於病歷記載：臨床整體評估表之分數；(3)日劑量超過 12 mg/day 時，須於病歷記載理由（91/9/1、92/1/1、92/7/1、94/1/1、95/10/1、97/5/1、99/10/1）。
2.本類藥品不得使用於雙極性疾患之鬱症發作。(95/10/1)